HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief

This article was originally published in The Rose Sheet

Executive Summary

The “Chemical Safety Improvement Act of 2013” would reform chemicals regulation in the U.S. by requiring manufacturers to submit safety data and prioritizing high-risk substances for further evaluation by the Environmental Protection Agency. More news in brief.

You may also be interested in...

Coty Projects Slight Q1 Decline, Citing “Drastic Drop” In Nail Segment

Coty is holding off on full-year projections until it gains visibility into the back-to-school and Christmas seasons, but expects first-quarter revenues to be down, largely due to a significant decline in nail-care consumption. The newly public firm looks to offset retailer destocking with innovations across its portfolio, previewed during its fiscal 2013 fourth-quarter and year-end earnings call.

Chemical Safety Improvement Act Promises Stronger EPA Oversight

Introduced by New Jersey Sen. Frank Lautenberg, the Chemical Safety Improvement Act of 2013 would give EPA authority to evaluate chemicals in commerce based on risk to human health and the environment and take action on those deemed unsafe. The bill would update the current Toxic Substances Control Act and potentially impact manufacturers of cosmetic ingredients.

In Brief

FDA issued warning letters Sept. 21 to two skin-care companies it says are making unapproved drug claims. More news in brief.

Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts